🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eloquence personified! A whirlwind of an overview of the last 25 years' development of antibody therapies in lymphoma. Peter Johnson giving his brilliant John Ultmann memorial lecture at #17ICML.

#ICML17 Stefano Luminari, MD Philip Hatcher-Moore presents new MZL IPI with 5 factors LDH ALC HbPlts and MZL subtype validated in external dataset Mayo Clinic

Article today in Lancet highlights only 1/3 invited lymphoma authors at top journals are women. Important perspective and suggestions for change from Women in Lymphoma - [email protected] Eliza hawkes thelancet.com/journals/lance…

A new benchmark dataset to standardise the way Metabolic Tumour Volume (MTV) is measured in lymphoma patients is now publicly available thanks to an international collaboration by researchers. kcl.ac.uk/news/new-bench…

👉Catch up with #IndolentLymphoma Session 3 cottereau anne segolene clementine sarkozy 🔗Recording us06web.zoom.us/rec/share/lliW… #lymphoma #lymsm With thanks to Gilead Sciences #IFLI Eli Lilly and Company Lymphoma Australia

Mike Bennett Memorial lecture from Pr Catherine Thieblemont Lysa Lymphoma Women in Lymphoma - [email protected] at UK lymphoma research group annual meeting Lymphoma Research UK reports exciting times ahead as unprecedented anti tumor activity in RR DLBCL of CART and bispecifics moves into 1st line

Pr Catherine Thieblemont Lysa Lymphoma Women in Lymphoma - [email protected] Lymphoma Research UK meeting - MTV & ENsites on PET and LDH used routinely to select for CART in France. Time for MTV in routine practice in UK with new international benchmark jnm.snmjournals.org/content/early/… KCL/GSTT PET centre Biomedical Engineering & Imaging Sciences

We see the elevation of glofitamab from 3rd line+ DLBCL to 2nd line+ combined with R-GemOx with STARGLO. Will it reach 1st line DLBCL? We await with interest results from the fully recruited SKYGLO study (Pola-R-CHP vs glofit-Pola-R-CHP).

Patients at Guy's and St Thomas' will benefit from a full-body scanner that will enable more effective diagnosis of patients with serious diseases. It will feed findings into the National PET Imaging Platform, building a bank of data from patients to support development of new medicines.

Watch Dr Sohaib Nazir, Clinical Senior Lecturer and Consultant Cardiologist at #Kingsimaging, explain how our new Total Body PET scanner will benefit healthcare research and improve patient outcomes🏥⬇️ #MedTech #Healthcare

A great reminder that cutting-edge large axial field-of-view "#TotalBodyPET scanners not only allow entirely new research avenues but also benefit patients immediately! #PET #KingsCollegeLondon #GSTT #NPIP #ImperialCollegeLondon

Number 3 #LeonardList #ASH24 top #lymphoma abstract 235 – Lewis – Ibrutinib-R v chemo-R in pts w/untreated MCL (Enrich) – How would newer BTKi do? BTKi upfront similar to B-R. We know BTKi effective 2ndline p chemo-R, chemo role after upfront BTKi unknown! ash.confex.com/ash/2024/webpr…

⚕️ Women in Lymphoma - [email protected] Steering Committee members, advocates, sponsors and supporters from all over the world🌍networking and sharing connections, initiatives and experience at #ASH24 #lymsm #lymphoma ASH

Michael Hofman ProsTIC Ian Davis ANZUP SNMMI European Association of Urology (EAU) European Association of Nuclear Medicine (EANM) Theranostics AANMS ANZSNM Ken Herrmann We would like to inform you that your post has been published on @Oncodaily. Thank you for sharing! oncodaily.com/insight/211624

For the first time ever the UK has more female than male doctors, with 164 440 women (50.04%) and 164 195 men (49.96%) registered with a licence to practise, show data from the GMC bmj.com/content/388/bm…

We are seeking a clinical trial co-ordinator who wants to make a true impact... at Peter Mac Cancer Centre . you’ll lead the coordination of our ProsTIC clinical trials, building on more than a decade of global leadership in cutting-edge research. Why Join Us? ⦿ Global Recognition: We

Abstract deadline approaching May31 for submissions to #PILM2025. Come join us to discuss hot topics in lymphoma and myeloma in beautiful Menton France 12-13 September 2025 cottereau anne segolene C. Thieblemont Irène Buvat @AndreaGallamini3 lymphomapet.com linkedin.com/feed/update/ur…

"While the UK is a global leader in clinical research, many solutions to today’s complex health challenges - such as reducing the lives lost to the biggest killers - will come from working together across borders." 🫱🏽‍🫲🏼🌏 📝 In her latest blog, our CEO Professor Lucy Chappell

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3

Timely tour de force review on Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology Toby Eyre ascopubs.org/doi/full/10.12…